Immunotherapy with interleukin-2 (IL-2) and lymphokineactivated killer (LAK) cells results in significant tumor regression in patients with advanced cancer. We have investigated the kinetics of circulating erythroid (BFU-E) and granulocyticmacrophage (CFU-GM) progenitors after IL-2 therapy in 11 cancer patients, mainly affected by metastatic melanoma and renal cell carcinoma. Administration of IL-2 from day 1 through day 5 constantly induced a dramatic decrease of the number of circulating BFU-E and CFU-GM, which then showed a striking rebound (up t o values fourfold and sevenfold higher, respectively, than the pretherapy levels) on discontinuation of IL-2, ie, from day 5 through day I O . A similar kinetic pattern was observed during and after the second cycle of IL-2 administration. 3[H]-thymidine killing experiments showed that the cycling activity of the progenitors was virtually unmodified in the rebound phases. To explore the HE THERAPEUTIC potential of interleukin-2 (IL-2)
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HE THERAPEUTIC potential of interleukin-2 (IL-2)
T for the treatment of human cancer has been extensively investigated.'.'' In cell cultures, IL-2 activates not only the lymphocytes that mediate the major histocompatibility complex-restricted recognition of specific target cells, but also the natural killer (NK) lymphocytes, which lyse in vitro particular tumor targets. The lymphokine-activated killer (LAK) cells, obtained by culturing peripheral blood lymphocytes (PBL) with IL-2; exhibit the capacity of lysing a wide range of fresh/cultured malignant cells and virally transformed normal tissues with minimal destruction of normal cell^.^*^ Clinical trials have shown that significant antitumor responses are observed in a minority of patients with disseminated malignancies following infusion of large dosages of IL-2, combined or not combined with LAK cell^.'^^'^ However, severe toxicity is associated with high-dose IL-2 IL-2 administration induces a series of secondary effects on the hematopoietic system. A progressive anemia may develop, which often requires blood transfusion, particularly in high-dose trials." Thrombocytopenia may occasionally be monitored." On the other hand, no consistent changes in circulating neutrophils have been observed. However, after prolonged IL-2 therapy, eosinophilia may develop." In two patients, these hematologic changes were associated with a decrease in circulating erythroid (burst forming unit-erythroid [BFU-E]) and granulocytic-macrophage (colony-forming unit-granulo monocytic [CFU-GM]) progenitors." The mechanism(s) underlying this hematopoietic suppression may relate to the induction of interferon-y (IFN-y)'9,20 and tumor necrosis factor-a (TNF-CX),~',~~ which synergize in the suppression of hematopoietic progenitors.u As with other IL-2-related side effects, the hematologic changes rapidly reverse on cessation of therapy."
We have investigated the fluctuations of the number of peripheral blood hematopoietic progenitors (BFU-E and CFU-GM) in 11 cancer patients undergoing adoptive immumechanism(s) underlying this kinetic pattern, we have analyzed the plasma concentration of several hematopoietic growth factors, including IL-1 p, IL-3, IL-4, IL-6, granulocytemacrophage colony-stimulating factor (GM-CSF), G-CSF, and erythropoietin (Ep). No modifications in the levels of IL-3, GM-CSF, or IL-1p were observed, whereas a pronounced increase of IL-6 and G-CSF concentration was monitored, starting at day 3 and peaking at day 5 of treatment (a parallel, but modest, increase of Ep level was also observed). The elevation of IL-6 and G-CSF concentration is directly correlated with and may, at least in part, underlie the subsequent rebound of circulating hematopoietic progenitors. Furthermore, the increase in IL-4 level observed at day 10 of therapy may mediate the eosinophilia gradually starting at this stage of treatment. o 1991 b y The American Society of Hematology.
notherapy with high-dose IL-2 bolus infusion and LAK cells. In all cases, IL-2 administration caused a marked reduction in the number of circulating BFU-E and CFU-GM, which is followed by a striking rebound when the IL-2 therapy is discontinued. This phenomenon is not associated with a modification of the cycling activity of hematopoietic progenitors, as assayed by [3H]-thymidine killing, but is seemingly related to a pronounced increase in the concentration of IL-6 and granulocyte colony-stimulating factor (G-CSF) preceding the rebound. (National Institutes of Health, Bethesda, MD), at a dosage of 4.5 or 6 x lo6 U/mZ of body surface by bolus intravenous (IV) infusion every 8 hours on day 1 through day 5. Some infusions were omitted because of lack of tolerance; however, no patient received less than 12 doses (mean value, 14). Following 2 days of rest, the patients underwent four leukaphereses on 4 consecutive days (8 through 11) to obtain peripheral blood mononuclear cells (PBMC). Leukaphereses were performed with a continuous-flow cell separator (IBM-2997; Cobe Laboratories, Lakewood, CO) essentially as described by Rosenberg et al.I4 PBMC were isolated and cultured as described below to generate LAK cells, which were then administered to patients by a central venous catheter for approximately 30 minutes on days 12, 13, and 15. IL-2 was administered during LAK infusion (4.5 or 6 x 106 U/m2 body surface every 8 hours for 5 days) starting immediately after the first LAK cell infusion on day 12.
For monitoring purposes and to facilitate management of IL-2 toxicity, all patients were hospitalized in an intensive care unit during both priming infusions of IL-2 and administration of IL-2 and LAK cells. Most patients received acetaminophen, indomethacin, and ranitidine during treatment. Hypotension was treated with fluid replacement and liberal use of the vasopressors, dopamine, and phenylephrine.
IL-2 (specific activity, 1.2 to 1.5 x 10' Biological Response Modifier's Program U/mg protein) was supplied as a lyophilized powder containing 25 mg human serum albumin and 5 mg mannitol/106 U and reconstituted in 100 mL sterile normal saline for each bolus injection.
Cells obtained by a 4-hour leukapheresis were delivered to the laboratory in a Fenwal transfer pack (Fenwal Laboratories, Deerfield, IL) at a final volume of 400 to 500 mL. The cell suspension was diluted 1:2 with calcium-and magnesium-free Hank's solution (HBSS) and layered on lymphocyte separation medium (LSM, Ficoll-Hypaque; Pharmacia, Uppsala, Sweden) in 50-mL conical centrifuge tubes (30-mL cell suspension, 20 mL LSM per tube). LSM gradients were centrifuged at 90% for 15 minutes. The plasma and platelet-rich supernatants were removed by vacuum suction and the mononuclear cell bands recovered and pooled in 250-mL conical centrifuge tubes (Corning 25350; Corning Glass Works, Corning, NY).
Mononuclear cells were washed three times with 200 mL HBSS and the cell pellets collected by centrifugation at 500g for 15 minutes after each wash. After the second wash, cells were resuspended in 200 mL HBSS and counted. Cell viability, as evaluated by trypan blue exclusion, generally exceeded 95%. Following a final centrifugation at 5oOg, cells were cultured at a concentration of 1.5 x lo6 cells/mL in 2.3-L roller bottles containing 500 mL of complete LAK activation medium (RPMI 1640 containing 2 mmol/L L-glutamine, penicillin, streptomycin, and gentamycin, 2.5% heat-inactivated and 0.22 kmol/L filtered human AB serum). rIL-2 (Hoffman-La Roche) was added to achieve a final concentration of 1,500 U/mL (0.75 x lo6 Uiroller bottle). Roller bottles were tightly capped and incubated for 3 to 4 days in a 37°C incubator with a rotating rate of 0.5 to 1.0 rpm.
To harvest cells from the roller bottle the LAK cell suspension was centrifuged at 1,500 rpm/l5 minutes in 250-mL centrifuge bottles (Corning). Cell pellets were pooled in 250-mL conical centrifuge tubes and washed twice with HBSS without phenol red. All cells were pooled after the first wash. After the second wash, cells were resuspended in 200 mL of 0.9% NaCl solution and counted. Viability, as evaluated by trypan blue exclusion, generally exceeded 95%. Cells were resuspended in 200 mL infusion medium (40 mL of 25% human serum albumin, 160 mL 0.9% NaCl solution for infusion, 200,000 U rIL-2). Finally, the cell suspension was filtered through sterile 110 mesh (Millipore, Malsheim, France) and transferred to a Fenwall transfer pack for infusion into the patient. LAK activity was assayed in a standard chromium release cytotoxicity assay system.
Clonogenic assay of peripheral blood hematopoietic progenitors. Blood samples (20 mL) were collected in preservative-free heparin and separated over a Ficoll-Hypaque density gradient (density 2 1.077) (Pharmacia Fine Chemicals, Piscataway, NJ) at 400g for 40 minutes at 2OOC. Z4 The interface mononuclear cells were collected, washed twice, and resuspended in Iscove's modified Dulbecco's medium (IMDM).
PBMC were cultured at a concentration of 3 X 10' cells/mL/dish (three plates per point) in 0.9% methylcellulose, 40% fetal calf serum (FCS; Flow Laboratories, Glasgow, UK) in IMDM supplemented with a-thioglycerol mol& Sigma, St Louis, MO) at 37°C in a 5% CO, humidified atmosphere. For BFU-E colony assay, 3 U of recombinant human erythropoietin (Ep; Amgen, Thousand Oaks, CA) was added; for CFU-GM colony assay, 10 ng/mL of recombinant human granulocyte-macrophage CSF (GM-C S F Sandoz, Milan, Italy) was added.
Colonies were scored at days 14 through 15 of culture under an inverted microscope. Data are expressed as the number (mean ? SEM values) of colonies per milliliter of blood.
To evaluate the experimental variability of the colony assay of hematopoietic progenitors, PBMC derived from a normal donor were stored in aliquots in liquid nitrogen. In each experiment one aliquot was thawed and plated as described above: the number of Generation of LAK cells.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From BFU-E and CFU-GM/3 x 10s PBMC was 62 f 3 and 37 f 2.7, respectively (mean f SEM values).
In the ['HI-thymidine killing assay, 2 x lo6 PBMC resuspended in 1 mL IMDM were incubated for 30 minutes at 37°C in the presence of (a) no additives (control); (b) 20 p,Ci/mL ['HI-thymidine (20 L/mmol; New England Nuclear, Boston, MA); (c) 100 hCi/mL ['HI-thymidine; (d) 100 XCi/mL ['HI-thymidine plus an excess of unlabeled Cells were then washed three times in 10 mL of IMDM medium containing 10% FCS and plated for clonogenic assays.
To calculate the percentage of killed progenitors, the number of BFU-E or CFU-GM colonies in b + c was divided by a + d and multiplied by 100 (b +c/a + d x 100).
Plasma samples for cytokine evaluation were derived from blood samples drawn in plastic tubes containing EDTA and the protease inhibitor aprotinin (10 U/mL). Blood samples were centrifuged for 15 minutes at 4,000 rpm; plasma was recovered and stored in aliquots at -80°C.
GM-CSF and IL-4 were evaluated by commercial immunoenzymatic kits: the threshold of detection is 5 pg/mL (Genzyme, Boston, MA). IL-6 and IL-3 were evaluated by immunoenzymatic methods, which detect concentrations as low as 5 pg/mL (British Biotechnology, Cowly, Oxford, UK). Ep plasma concentration was quantitated using a sensitive immunoenzymatic method (threshold of detection 1 to 2 mU/mL) (Biosoft, Frankfurt, Germany). G-CSF plasma concentration was measured by a sensitive immunoenzymatic assay, which detects as little as 20 pg/mL (Oncogene Science,
Manhasset, NY).
The Student's t-test was used to compare groups of data of equal size. Linear regression analysis was used to evaluate the correlation between the increase of hematopoietic progenitors and the corresponding increase in plasma cytokine level.
'[HI-thymidine killing assay.
Evaluation of cytokine plasma samples.
Statistical analysis.

RESULTS
Standard hematologicparameter.
Evaluation of the standard hematologic parameters (Table 2) showed: (a) a moderate decrease in the number of red blood cells (RBCs) and Hb level starting from day 5; (b) a slight increase in the number of neutrophils, with a marked increase in the number of eosinophils at day 15 through day 18 of treatment; (c) a pronounced decrease in the number of platelets, particularly at day 5 of therapy.
The number of circulating hematopoietic progenitors was evaluated at different days during IL-2 + LAK cell therapy (Fig 2) .
During the initial 5 days of IL-2 treatment, a marked decrease in the number of circulating BFU-E and CFU-GM was observed. Particularly, at day 3 the number of circulating BFU-E and CFU-GM corresponded to 8% and 15%, respectively, of pretherapy values. A slight rebound initi-
Circulating hematopoietic progenitors.
ated on day 5. At days 8 and 10 a striking increase in the number of circulating BFU-E and CFU-GM was observed, reaching values fourfold to sevenfold higher, respectively, than the pretreatment values. During the second cycle of IL-2 + LAK cell therapy, the number of circulating BFU-E and CFU-GM decreased again, thus reaching on day 15 nadir values slightly above starting levels. The fluctuations in the number of hematopoietic progenitors observed during and after IL-2 therapy are statistically significant, and are obviously not related to the low intrinsic variability of the colony assay (see Materials and Methods).
Interestingly, the kinetic pattern of circulating hematopoietic progenitors during IL-2 therapy strictly parallels that of PBL: nadir or peak values of both lymphocytes and hematopoietic progenitors are observed at days 3 through 5 and 15, or 8 through 10 and 18 of the first and second cycle of therapy (Fig 2) . It is of interest that the fluctuations in the number of circulating lymphocytes occur in different lymphocyte subsets, including total T lymphocytes (CD3'), T-helper lymphocytes (CD4+), T-cytotoxic/suppressor lymphocytes (CD8'), and NK lymphocytes (CD56') (Fig 3) . Particularly relevant is the rebound of CD8' and CD56' cells after discontinuation of IL-2 administration (Fig 3) .
'[HI-thymidine killing experiments were performed in two patients to evaluate the cycling activity of BFU-E and CFU-GM at different times during IL-2 therapy. The percentage of killed progenitors in two representative cases was virtually unmodified at days 8 and 15 of therapy (Table  3) . This preliminary observation suggests that the marked fluctuations in the number of hematopoietic progenitors following IL-2 administration are not associated with a modification in their cell cycle status.
Evaluation of circulating hematopoietic growth factors (GFs).
It is well established that the proliferation and differentiation of hematopoietic progenitors is controlled by specific hematopoietic GFs." Thus, it seemed of interest to investigate whether the marked rebound in the number of circulating hematopoietic progenitors is related to an increase in the plasma concentration of one or more hematopoietins, including Ep, IL-lp, IL-3, IL-4, IL-6, GM-CSF, and G-CSF. The results showed that: (a) In four of nine patients affected by melanoma or renal carcinoma, plasma Ep concentration showed a threefold increase (64 2 17 mU/mL) on day 5 and then a decrease at days 8 and 10 ( Table 4 ). (b) All patients showed a pronounced increase of plasma IL-6 concentration from pretreatment values (4 f 0.9 ng/mL) up to day 3 levels (29 * 6) and peak values on day 5 (123 * 55). The concentration then de- 
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creased to pretherapy levels on day 8 through day 10 (Fig 4,  Table 5 ). (c) Except for a single case, plasma G-CSF concentrations showed a significant, marked increase at days 3 and 5, but generally decreased on day 8 (Table 6) .
(d)
In seven of eight patients, the plasma GM-CSF concentration was essentially unmodified on days 3, 5 , and 8 of treatment (data not shown). Only one patient exhibited a pronounced increase on days 5 and 8. (e) Plasma IL-4 levels ( Table 7) Correlation between plasma cytokine concentration and the number of circulating hematopoietic progenitors. To evaluate whether the increase in plasma concentration of Ep, IL-6, and G-CSF is responsible for the pronounced increase in the number of circulating hematopoietic progenitors during IL-2 therapy, we analyzed the correlation between the increase in progenitor cell number (ie, ratio between the peak level/pretherapy level) and in plasma cytokine level (ie, ratio between peawpretherapy level). This analysis showed a highly significant direct correlation (P < .01) between the increase of BFU-E number and the increase of in Ep, IL-6, and G-CSF concentration, as well as between the elevation in CFU-GM number and G-CSF level (Fig 5A  and B) . A less significant correlation was observed between the increase of CFU-GM number and IL-6 concentration (P < .05).
DISCUSSION
Preliminary results in two patients with advanced cancer suggest that high-dose IL-2 treatment induces a significant decrease in the number of circulating BFU-E and CFU-GM that rebounds after discontinuation of therapy." It was further suggested that the increase of IFN-y caused by IL-2 may underlie the initial decrease."
In an attempt to verify this preliminary observation, we have analyzed the kinetics of circulating BFU-E and CFU-GM in 11 patients undergoing an immunotherapy protocol, which essentially involves a first cycle of high-dose bolus IL-2 injection (days 1 through 5), a period of rest (days 6 and 7), four leukaphereses (days 8 through l l ) , and a second cycle of IL-2 + LAK cell therapy (days 12 through 16).
The results show conclusively that high-dose bolus IL-2 administration constantly causes a marked decrease of the number of circulating BFU-E and CFU-GM (8% to 11% of pretreatment values, respectively), which is followed by a striking rebound up to values fourfold to sevenfold higher than the pretreatment values. A similar kinetic pattern is observed during and after the second cycle of IL-2 therapy.
A second series of studies aimed to analyze the mecha- 1) . The data represent the mean & SEM values from 11 patients (see Table 1 ).
tors after discontinuation of IL-2 administration. Clonogenetic culture studies reported that IL-2 exerts either or p o~i t i v e '~.~~ effects on hematopoiesis. IL-2 may inhibit erythroid and GM colony formation in a Table 1 ).
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dose-dependent manner, via Tac+,28,2y 0KT8+,2933" NK, or LAK cells."-34 However, at low concentration^^^ and in the presence of T lymphocytes? IL-2 apparently stimulates erythroid and GM colony growth. These discrepancies may be attributed not only to the variability of clonogenic assays and the different dosages of IL-2, but particularly to the differential interactions in culture between IL-2, accessory cells releasing endogenous cytokines, and target progenitors. 
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Talmadge et a136 have analyzed the in vivo effect of IL-2 on murine hematopoiesis. Both acute and chronic IL-2 administration cause an increase in the frequency of GM hematopoietic progenitors in bone marrow. This effect was observed a few days after IL-2 administration. Furthermore, human rIL-2 accelerated the hematopoietic recovery from cyclophosphamide-or radiation-induced bone marrow depression and peripheral blood leukopenia. The myelostimulatory properties of IL-2 are dependent on host 
\
I
The moderate increase in Ep plasma concentration on day 5 might be related to the slight, gradual decrease in Hb level occurring from days 1 to 8 of therapy. In fact, it is well established that the release of Ep is inversely related to RBC mass and Hb c~ncentration."~~' However, the Ep concentration decreases to near-normal levels on days 8 and 10, whereas the Hb decrease persists at this phase of therapy. Further studies are clearly required to elucidate the significance of the stimulatory effect of IL-2 on Ep production.
It is noteworthy that IL-2 induced a 30-fold increase in IL-6 plasma concentration. This finding is in agreement with a previous report by Jablons et al." IL-6, usually T cells because they were abrogated in nude mice. Finally, the myelostimulatory effect of IL-2 was related to the release of hematopoietic GFs in the bone marrow microenvironment.
The myelostimulatory activity of IL-2 reported in mice is in line with the rebound of circulating hematopoietic virtually undetectable in the serum of normal individ~als,~' is produced by a variety of cells, particularly fibroblasts, monocytes-macrophages, and endothelial cell^.^'.^' Increased plasma levels of IL-6 were observed in sepsis4j and after GM-CSF administration." However, neither of these mechanisms may be advocated in our patients, because none presented sepsis or an increased GM-CSF level (with one exception). The cell type releasing IL-6 in patients treated with IL-2 has not been clarified: monocytesmacrophages are obvious candidates4' because they are activated in vivo (probably through the release of IFN-y) in patients undergoing adoptive immunotherapy with IL-2.22
In vitro IL-6 plays a synergistic role with IL-3 to induce proliferation of early hematopoietic progenitor~.~~,~' In vivo IL-6 stimulates hematopoiesis, particularly at the level of erythropoiesis, neutropoiesis, and thrombopoie~is.~~.~' This suggests that the IL-2-induced increase of this cytokine at days 3 through 5 may, in part, mediate the subsequent rebound of hematopoietic progenitors at days 5 through 10 For personal use only. on September 24, 2017. by guest www.bloodjournal.org From after interruption of IL-2 therapy. The IL-6 effect is conceivably enhanced by G-CSF, whose plasma levels show a sevenfold increase on days 3 through 5 of treatment.
It is also of interest that both IL-6 and G-CSF stimulate the formation of blast cell colonies with multiple hematopoietic lineage p~t e n t i a l .~~~'~ These findings suggest that IL-2 stimulates hematopoiesis through secondary cytokines, eg, IL-6 and G-CSF, which exert a pronounced stimulatory effect on the early stages of hematopoietic differentiation.
Finally, we frequently observed a late increase of plasma IL-4 at days 8 through 10 of therapy. This cytokine, together with IL-5 and IL-6,52.53 is involved in the production of eosinophils. Because eosinophilia initiates on day 11 and peaks on days 15 through 18, we suggest that the IL-4 increase may, at least in part, mediate this phenomenon.
In conclusion, it is apparent that the pleiotropic effects of high-dose IL-2 bolus infusion on hematopoietic cells are at least partially mediated by induction of secondary release of other cytokines, ie, IFN--y and TNF-a," as well as IL-6, G-CSF, and IL-4 (this report).
